CYP19A1 and diabetes mellitus: For example, a case-cohort study involving breast cancer survivors showed that adjuvant tamoxifen was associated with a 2.2 fold risk of diabetes whereas aromatase inhibitors were associated with a 4.2 fold risk of diabetes [98].